News and ViewsIs Janux Therapeutics, Inc. technically bullish or bearish?
2025-09-30 11:19:14As of 26 September 2025, the technical trend for Janux Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The moving averages indicate a bearish trend on the daily. Additionally, the Dow Theory and Bollinger Bands are both mildly bearish on the monthly timeframe. In terms of performance, Janux has underperformed the S&P 500 across multiple periods, with a year-to-date return of -56.61% compared to the S&P 500's 12.96%, and a one-year return of -50.17% versus 15.64% for the benchmark....
Read MoreIs Janux Therapeutics, Inc. technically bullish or bearish?
2025-09-29 11:20:08As of 26 September 2025, the technical trend for Janux Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating mild bullishness, while the monthly MACD remains bearish. The daily moving averages are bearish, and both the weekly and monthly Dow Theory are also mildly bearish. The stock has underperformed the S&P 500 significantly over the past month and year, with returns of -1.73% and -50.17%, respectively, compared to the S&P 500's gains of 2.75% and 15.64%....
Read MoreIs Janux Therapeutics, Inc. technically bullish or bearish?
2025-09-28 11:13:11As of 26 September 2025, the technical trend for Janux Therapeutics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating mild bullishness, while the monthly MACD remains bearish. The daily moving averages are bearish, and both the weekly and monthly Dow Theory suggest a mildly bearish outlook. Additionally, the Bollinger Bands are sideways on the weekly chart and mildly bearish on the monthly chart. In terms of performance, Janux has underperformed the S&P 500 across multiple periods, with a year-to-date return of -56.61% compared to the S&P 500's 12.96%, and a one-year return of -50.17% versus the S&P 500's 15.64%....
Read MoreIs Janux Therapeutics, Inc. technically bullish or bearish?
2025-09-20 20:08:33As of 19 May 2025, the technical trend for Janux Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are bearish, and the Bollinger Bands show a sideways trend on the weekly chart, with a mildly bearish outlook on the monthly. The KST is mildly bullish on the weekly and mildly bearish on the monthly, and the OBV is mildly bullish across both time frames. In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -54.43% compared to the S&P 500's 12.22%, and a one-year return of -49.5% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, indicating some weakness despite a few bullish signals on shorter time frames....
Read MoreIs Janux Therapeutics, Inc. overvalued or undervalued?
2025-09-20 18:40:57As of 7 August 2025, the valuation grade for Janux Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is considered overvalued given its current metrics, particularly with a Price to Book Value of 1.54, an EV to EBIT of -4.84, and an EV to EBITDA of -4.93, which reflect negative earnings performance. In comparison to its peer Avidity Biosciences, Inc., which has a P/E ratio of -13.5642 and an EV to EBITDA of -9.6438, Janux appears to be in a weaker position. The company's returns have also lagged significantly behind the S&P 500, with a year-to-date return of -54.43% compared to the index's 12.22%, reinforcing the perception of overvaluation....
Read More
Announcement
Corporate ActionsCorporate Actions
